

## Core PEAK Product References



Turpeinen, A.; Kumpu, M.; Rönback, M.; Seppo, L.; Kautiainen, H.; Jauhiainen, T.; Vapaatalo, H.; Korpela, R. Antihypertensive and cholesterol-lowering effects of a spread containing bioactive peptides IPP and VPP and plant sterols. *J. Funct. Food* 2009, 1, 260–265.

Turpeinen, A.; Ikonen, M.; Kivimäki, A.S.; Kautiainen, H.; Vapaatalo, H.; Korpela, R. A spread containing bioactive milk peptides Ile-Pro-Pro and Val-Pro-Pro, and plant sterols has antihypertensive and cholesterol-lowering effects. *Food Funct.* 2012, 3, 621–627.1

Jauhiainen, T.; Rönback, M.; Vapaatalo, H.; Wuolle, K.; Kautiainen, H.; Korpela, R. *Lactobacillus helveticus* fermented milk reduced arterial stiffness in hypertensive subjects. *Int. Dairy J.* 2007, 17, 1209–1211.

Unger, L.; Ibsen, H.; Linneberg, A.; Azizi, M.; Flambard, B.; Jensen, L. Human in vivo study of the renin-angiotensin-aldosterone system and the sympathetic activity after 8 weeks daily intake of fermented milk. *Clin. Physiol. Funct. Imaging* 2010, 30, 162–168.

Itakura, H.; Ikemoto, S.; Terada, S.; Konodo, K. The effect of sour milk on blood pressure in untreated hypertensive and normotensive subjects. *J. Jpn. Soc. Clin. Nutr.* 2001, 23, 26–31.

Hirota, T.; Ohki, K.; Kawagishi, R.; Kajimoto, Y.; Mizuno, S.; Nakamura, Y.; Kitakaze, M. Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: Contribution of the inhibitory action of angiotensin-converting enzyme. *Hypertens. Res.* 2007, 30, 489–496.

Yasuda, K.; Aihara, K.; Komazaki, K.; Mochii, M.; Nakamura, Y. Effect of large intake of tablets containing “lactotripeptides (VPP, IPP)” on blood pressure, pulse rate and clinical parameters in healthy volunteers. *J. Nutr. Food* 2001, 4, 63–72.

---

Ishida, Y.; Sagitani, A.; Kaneko, K.; Nakamura, Y.; Mizutani, J.; Masuda, O.; Watanabe, M.; Sato, S.; Shioya, N. Antihypertensive effects of the tablet containing “lactotripeptide (IPP, VPP)” in subjects with high normal blood pressure or mild hypertension. *J. Pharmacol. Ther.* 2007, 35, 1249–1260

Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. *The Journal of clinical endocrinology and metabolism*, 96(5), E782–E792. <https://doi.org/10.1210/jc.2010-2879>

Pla-Pagà, L., Companys, J., Calderón-Pérez, L., Llauradó, E., Solà, R., Valls, R. M., & Pedret, A. (2019). Effects of hesperidin consumption on cardiovascular risk biomarkers: a systematic review of animal studies and human randomized clinical trials. *Nutrition reviews*, 77(12), 845–864. <https://doi.org/10.1093/nutrit/nuz036>

Li, C., & Schluesener, H. (2017). Health-promoting effects of the citrus flavanone hesperidin. *Critical reviews in food science and nutrition*, 57(3), 613–631. <https://doi.org/10.1080/10408398.2014.906382>

Auguet M, et al. Selective inhibition of inducible nitric oxide synthase by agmatine. *Jpn J Pharmacol.* (1995)

Jianmongkol S, et al. Aminoguanidine-mediated inactivation and alteration of neuronal nitric-oxide synthase. *J Biol Chem.* (2000)

Wolff DJ, Lubeskie A. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. *Arch Biochem Biophys.* (1995)2

Nakatsuka M, Nakatsuka K, Osawa Y. Metabolism-based inactivation of penile nitric oxide synthase activity by guanabenz. *Drug Metab Dispos.* (1998)

Pahlavani, N., Jafari, M., Sadeghi, O., Rezaei, M., Rasad, H., Rahdar, H. A., & Entezari, M. H. (2014). L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial. *F1000Research*, 3, 306. <https://doi.org/10.12688/f1000research.5877.2>

McRae M. P. (2016). Therapeutic Benefits of L-Arginine: An Umbrella Review of Meta-analyses. *Journal of chiropractic medicine*, 15(3), 184–189. <https://doi.org/10.1016/j.jcm.2016.06.002>

Macuh, M.; Knap, B. Effects of Nitrate Supplementation on Exercise Performance in Humans: A Narrative Review. *Nutrients* 2021, 13, 3183. <https://doi.org/10.3390/nu13093183>

Rathmacher, J. A., Fuller, J. C., Jr, Baier, S. M., Abumrad, N. N., Angus, H. F., & Sharp, R. L. (2012). Adenosine-5'-triphosphate (ATP) supplementation improves low peak muscle torque and torque fatigue during repeated high intensity exercise sets. *Journal of the International Society of Sports Nutrition*, 9(1), 48. <https://doi.org/10.1186/1550-2783-9-48>

Arts, I. C., Coolen, E. J., Bours, M. J., Huyghebaert, N., Stuart, M. A., Bast, A., & Dagnelie, P. C. (2012). Adenosine 5'-triphosphate (ATP) supplements are not orally bioavailable: a randomized, placebo-controlled cross-over trial in healthy humans. *Journal of the International Society of Sports Nutrition*, 9(1), 16. <https://doi.org/10.1186/1550-2783-9-16>

Coolen, E. J., Arts, I. C., Bekers, O., Vervae, C., Bast, A., & Dagnelie, P. C. (2011). Oral bioavailability of ATP after prolonged administration. *The British journal of nutrition*, 105(3), 357–366. <https://doi.org/10.1017/S0007114510003570>

Purpura, M., Rathmacher, J. A., Sharp, M. H., Lowery, R. P., Shields, K. A., Partl, J. M., Wilson, J. M., & Jäger, R. (2017). Oral Adenosine-5'-triphosphate (ATP) Administration Increases Postexercise ATP Levels, Muscle Excitability, and Athletic Performance Following a Repeated Sprint Bout. *Journal of the American College of Nutrition*, 36(3), 177–183. <https://doi.org/10.1080/07315724.2016.1246989>

Wilson, J. M., Joy, J. M., Lowery, R. P., Roberts, M. D., Lockwood, C. M., Manninen, A. H., Fuller, J. C., De Souza, E. O., Baier, S. M., Wilson, S. M., & Rathmacher, J. A. (2013). Effects of oral adenosine-5'-triphosphate supplementation on athletic performance, skeletal muscle hypertrophy and recovery in resistance-trained men. *Nutrition & metabolism*, 10(1), 57. <https://doi.org/10.1186/1743-7075-10-57>